trending Market Intelligence /marketintelligence/en/news-insights/trending/d9feksyctz7pjhtxclgzla2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Seres Therapeutics adds former Novartis executive to board

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Seres Therapeutics adds former Novartis executive to board

Cambridge, Mass.-based biotechnology company Seres Therapeutics Inc. appointed Meryl Zausner as a board member.

Zausner previously served as chief financial and administrative officer of Novartis AG unit Novartis Pharmaceuticals Corp. and a member of the U.S. pharmaceutical executive committee and global finance leadership team.

Seres Therapeutics develops medicines using live bacteria to treat diseases resulting from functional deficiencies of microorganisms within the body.